-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$101.4696.13% Upside
Recent Analyst Forecasts and Stock Ratings
CRISPR Therapeutics AG Frequently Asked Questions
-
What analysts cover CRISPR Therapeutics AG?
CRISPR Therapeutics AG has been rated by research analysts at Oppenheimer, Leerink Partners, Truist Financial, Needham, Stifel Nicolaus, RBC Capital in the past 90 days.